1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"DARPA-SN-26-67DNA-Protein Epigenetic Chemistry Engineering (D-PECHE)" is currently closed and not accepting applications.
DARPA-SN-26-67DNA-Protein Epigenetic Chemistry Engineering (D-PECHE) is sponsored by DARPA Biological Technologies Office. D-PECHE seeks to demonstrate novel mechanisms to write/erase DNA epigenetic base modifications in living cells.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
# DNA-Protein Epigenetic Chemistry Engineering (D-PECHE) | DARPA A **. mil** website belongs to an official U.S. Department of War organization. * [](https://www.
darpa. mil/search) [](https://www. darpa.
mil/search) [](https://www. darpa. mil/work-with-us/opportunities/darpa-sn-26-67) 4.
DNA-Protein Epigenetic Chemistry Engineering (D-PECHE) # DNA-Protein Epigenetic Chemistry Engineering (D-PECHE) D-PECHE seeks to demonstrate novel mechanisms to write/erase DNA epigenetic base modifications in living cells. * **Published:** May 6, 2026 * **Deadline:** June 24, 2026 Biological Technologies Office * Other BTO Opportunities Embark on a journey of innovation and impact! Tell us about your interest in DARPA.
**Please note: Fields marked with an asterisk are required. ** Program Manager (Optional) Be part of a cutting-edge research and development agency that’s pushing the boundaries of what’s possible, in an energetic environment with excellent benefits. Find your future with DARPA Careers> Our program managers are visionary leaders whose experience spans industry, government, and academia.
They conceive, plan, and oversee the high-risk R&D efforts for which we are best known. DARPA has pushed, and will continue to push, the boundaries of technological possibility.
See the dreams we turned to reality #### **Defense Advanced Research Projects Agency** To create and prevent technological surprise for our national security * Investors & Entrepreneurs * Biological Technologies * Information Processing Techniques * Podcast (Voices from DARPA)") * Communications & Public Affairs * The Heilmeier Catechism * Accessibility/Section 508 * Request a DARPA speaker * Freedom of Information Act * Privacy and Civil Liberties
According to the current listing, eligibility includes: Open to all qualified organizations. Confirm the full requirements in the official notice before applying.
The published deadline was May 28, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
DARPA-SN-26-67DNA-Protein Epigenetic Chemistry Engineering (D-PECHE) is funded by DARPA Biological Technologies Office. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDPA26BZ06-DV026 offers $300,000 at Phase I or $1,800,000 as a single Direct-to-Phase-II tranche with no options. The deliverable is a simulated auction market that measures whether AI agents deceive, collude, or manipulate the humans they serve — measured entirely from the outside. Here is the 90% efficiency gate, the team composition most bidders will get wrong, and why this topic sits in DARPA's biology office.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read article